stoxline Quote Chart Rank Option Currency Glossary
  
(AGTC)
  0 (0%)    09-27 11:14
Open:
High:
Volume: 0
  
Pre. Close:
Low:
Market Cap: 0(M)
Technical analysis
2023-01-06 4:29:02 PM
Short term     
Mid term     
Targets 6-month :  0.49 1-year :  0.57
Resists First :  0.42 Second :  0.49
Pivot price 0.38
Supports First :  0.38 Second :  0.36
MAs MA(5) :  0.39 MA(20) :  0.38
MA(100) :  0.36 MA(250) :  0.93
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  83.9 D(3) :  83.9
RSI RSI(14): 60
52-week High :  2.82 Low :  0.23
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ AGTC ] has closed below upper band by 28.7%. Bollinger Bands are 77.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.39 - 0.4 0.4 - 0.4
Low: 0.39 - 0.39 0.39 - 0.39
Close: 0.39 - 0.39 0.39 - 0.4
Company Description

Headline News

Thu, 19 Jun 2025
AGTC 2025: Port congestion & Middle Eastern conflicts complicate vessel schedules - American Journal of Transportation

Sat, 12 Apr 2025
IAGTO’s three global golf tourism conventions fully booked for 2025 - Sports Tourism News

Fri, 04 Apr 2025
Asia Golf Tourism Convention puts spotlight on Central Vietnam - Golf Business News

Mon, 03 Feb 2025
FDA grants RMAT designation to Beacon Therapeutics XLRP gene therapy - Eyes On Eyecare

Tue, 28 Jan 2025
Beacon Therapeutics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for laru-zova (AGTC-501) - PR Newswire

Tue, 10 Dec 2024
Beacon Therapeutics announces positive 3-month data from Phase 2 DAWN trial of AGTC-501 in patients with X-linked retinitis pigmentosa - Ophthalmology Times

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
Sector:
Industry:
Shares Out 0 (M)
Shares Float 68 (M)
Held by Insiders 6.063e+007 (%)
Held by Institutions 0.8 (%)
Shares Short 1,790 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -6.466e+007
EPS Est Next Qtrly 0.02
EPS Est This Year -0.82
EPS Est Next Year -1.64
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -20 %
Return on Assets (ttm) 361.5 %
Return on Equity (ttm) -42.8 %
Qtrly Rev. Growth 325000 %
Gross Profit (p.s.) -22.16
Sales Per Share -75.7
EBITDA (p.s.) -1.35696e+007
Qtrly Earnings Growth -1.5 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -66 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 1.07
Stock Dividends
Dividend 0
Forward Dividend 2.1e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android